Clinical Trial Update: A Research Trial of Aralast in New Onset Diabetes (RETAIN) [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating Aralast for new-onset Type 1 diabetes was terminated, with results posted in January 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Aralast (alpha-1 antitrypsin)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Diabetes Mellitus, Type 1 | Phase 1 | Status: TERMINATED | Results posted: 2015-01-16